License out
JAK1 inhibitor SHR0302 out-licensed to Arcutis (USA)
BTK inhibitor SHR1459 out-licensed to TG Therapeutics (USA)
Camrelizumab out-licensed to Crystal Genomics (South Korea)
Pyrotinib out-licensed to HLB-LS (South Korea)
SHR-1701 out-licensed to DONG-A ST CO., LTD. (South Korea)
EZH2 inhibitor SHR2554 out-licensed to Treeline Biosciences (USA)
TSLP McAb (SHR-1905) out-licensed to Aiolos Bio (USA)
HER1/HER2/HER4 targeted drug (Pyrotinib maleate tablets) out-licensed to Dr.Reddy's (India)
Combination therapy of PD-1 inhibitor Camrelizumab for liver cancer out-licensed to Elevar Therapeutics (USA)
PARP1 inhibitor HRS-1167, Claudin-18.2 ADC SHR-A1904 out-licensed to Merck KGaA (Germany)
Product portfolio of GLP-1 innovative drugs out-licensed to Kailera (USA)
DLL3 ADC innovative drug (SHR-4849) out-licensed to IDEAYA Biosciences (USA)
Lp(a) inhibitor (HRS-5346) out-licensed to MSD
Cooperation with Merck KGaA (Germany) to promote the commercialization of oral GnRH antagonists
Cooperation with GSK to develop up to 12 innovative drugs covering Respiratory, Immunology & Inflammation(RI&I) and Oncology, including an worldwide
license (excluding mainland China, Hong Kong SAR, Macau SAR and Taiwan region) for PDE3/4 inhibitor HRS-9821
Myosin inhibitor (HRS-1893) out-licensed to Braveheart Bio
License in
Antifungal product VT-1161 introduced from Mycovia (USA) has been approved for sale with the name of Oteseconazole
CyclASol® and NOV03, drugs for xerophthalmia introduced from Novaliq (Germany)
A strategic cooperation reached with YL-PHARMA on a breakthrough therapy (PI3kδ inhibitor), which has been approved for sale as Linperlisib.
A strategic cooperation reached with Cstone Pharmaceuticals on anti-CTLA-4 McAb (CS1002)